(Editors' Note: This article discusses a micro-cap stock. Please be aware of the risks associated with these stocks.)
Taking a small test and having your future health outlined for you may seem like science fiction, but the ability to assess human health and potential for disease is getting to that point, if not already there. For some the concept may not seem comforting, but for others, knowing that a potential exists will enable fast and early treatment, thus avoiding a terrible fate that might have come.
CombiMatrix (CBMX) is a company that conducts DNA-based genomic testing services in the areas of Prenatal and Pediatric developmental disorders and Oncology. The company carries a $12 million dollar market cap...
Only subscribers can access this article, which is part of the PRO research library covering 3,600 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: